LEUKAPHERESIS IN SELECTED PATIENTS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。已经充分确定，肿瘤可以引发免疫应答，并且靶向免疫应答的策略可以导致肿瘤消退。然而，肿瘤识别和破坏的精确机制仍然没有充分定义，并且实验室中的抗肿瘤免疫与肿瘤大小的临床减小的相关性一直很困难。 由于UCHC对肿瘤免疫学的长期兴趣，许多患者已经接受了某种类型的免疫疗法或肿瘤疫苗的临床试验。详细分析这些患者对肿瘤的反应能力可能有助于更好地了解对癌症的免疫反应，并有助于开发更有效的治疗方法。 本方案建议进行门诊白细胞去除术，以增加可用于研究的患者淋巴细胞数量。这将对先前在UCHC接受肿瘤疫苗方案治疗的患者以及少数正常对照进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It has been well-established that tumors can elicit an immune response and that strategies which target the immune response can result in tumor regression. However, the precise mechanisms for tumor recognition and destruction remain inadequately defined, and correlation of anti-tumor immunity in the lab with clinical reductions in tumor size has been difficult. Because of the longstanding interest at UCHC in tumor immunology, many patients have been treated on clinical trials with some type of immunotherapy or tumor vaccine. Detailed analysis of the ability of these patients to respond to tumors may contribute to better understanding of the immune response to cancer and to the development of more effective therapies. This protocol proposes to perform outpatient leukapheresis to increase the number of patient lymphocytes available for study. This will be performed on patients who have previously been treated on a tumor vaccine protocol at UCHC, and also on a small number of normal controls.